Clinical trial · Observational
VEGF Imaging in Renal Cell Carcinoma
89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Sunitinib or Bevacizumab Plus Interferon; a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with sunitinib or bevacizumab plus interferon in patients with RCC. 89Zr-bevacizumab PET imaging will be regarded a promising biomarker if the target for treatment (VEGF) can be visualised and if uptake changes after institution of treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 89Zr-Bevacizumab PET-scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A
- description
- Treatment with sunitinib.
- interventionNames
- Other: 89Zr-Bevacizumab PET-scan
- label
- Group B
- description
- Treatment with bevacizumab and interferon
- interventionNames
- Other: 89Zr-Bevacizumab PET-scan
Primary outcomes (1)
- measure
- The primary endpoint is the change in SUV between baseline 89Zr-bevacizumab PET scan and the scan performed after 2 and 6 weeks of treatment with sunitinib or bevacizumab plus interferon in patients with RCC.
- timeFrame
- after 2 and 6 weeks
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * locally advanced irresectable or metastatic renal cell cancer * no untreated brain metastases (CT or MRI not necessary in the absence of symptoms) * no uncontrolled hypertension * no clinically significant cardiovascular events or disease during the last 12 months * no surgery in the last 4 weeks * no treatment with bevacizumab or another monoclonal antibody with anti-angiogenic properties in the last 4 months * no treatment with a tyrosine kinase inhibitor during the last 4 weeks * measurable disease with x-ray or CT scan, at least one site of disease must be unidimensionally measurable as follows: X-ray \> 20 mm, Spiral CT scan \> 10 mm, non-spiral CT scan \> 20 mm * clear cell histology component * not pregnant or nursing * women of childbearing potential must use effective contraception * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial * before patient randomization, written informed consent must be given according to GCP, and local regulations
References
Publications (0)
Data not yet available